The Michael J. Fox Foundation for Parkinson's Research’s Post

Identity of company ‐-------------------------------- Therasid Bioscience is dedicated to NASH therapeutics, so all the pipelines of company are addressed to NASH indication. Therasid deal with steatosis, inflammation and fibrosis as each representative disease activities of NASH. Our mid-term goal is treating NASH-fibrosis by a direct fibrosis resolving mechanism of actions. Therasid's ultimate goals in this field are investigation of current pathogenesis and discoveries of new pathogenesis for the cure of NASH.

[Clinical Trials] Vicore Pharma AB's phase 2a trial of Digital therapy Almee shows a 2.7-point improvement in anxiety symptoms in Anxiety with Pulmonary Fibrosis https://lnkd.in/gY3DpKM3 Soligenix, Inc.'s phase 2a trial of SGX302 demonstrates positive outcomes in treating psoriasis https://lnkd.in/g5S5ce7i Theravance Biopharma US, Inc.'s phase 4 study of YUPELRI reveals no significant difference from Spiriva HandiHaler in COPD https://lnkd.in/gbe-e-6a Jiangsu Simcere Pharmaceutical's phase 3 trial of BD0801 met primary endpoint in ovarian cancer, fallopian tube cancer, and peritoneal cancer patients https://lnkd.in/gRcDwvt5 Stayble Therapeutics' phase 2b trial of STA363 for chronic disc-related back pain did not achieve primary objective https://lnkd.in/g9jTpNY7

On 15 Nov, join the webinar “Where do biosimilars fit into the Cancer treatment puzzle?” to get an overview of the benefits that #BiosimilarMedicines can provide to #CancerCare and join #GlobalBiosimilarsWeek #GBW23 🧪

Don't forget to join Vigeo Therapeutics COO Dr. Jing Watnick updating the Fifth Annual Glioblastoma Drug Development Summit TODAY at 1:30 PM EDT today (March 28) in Boston, MA. Dr. Watnick will give an overview of #VT1021 in our Ph1/2 program in GBM as well as the future use of #VT1021 in attacking the roots of Neuro-inflammatory disease #GBM #Glioblastoma #NeurodegenerativeDisease #NeuroInflammatoryDisease #GBMSummit

********EARLY BIRD ALERT*********** It is early bird week for the 4th B&T Cell Mediated Autoimmune Disease Drug Development Summit! Looking achieve more targeted B cell modulation and depletion in autoimmunity? Attend the 4th B&T Cell Mediated Autoimmune Disease Drug Development to distinguish pathogenic B cells, move beyond lineage depleting strategies, overcome tissue specific delivery challenges and achieve broader efficacy in wider autoimmune patient populations. Join the likes of Namita Gandhi, Andreas Radbruch, Shawn Rose MD, PhD, Carrie Saulsbery, Michael Howell, Kira Rubtsova, Taylor L. Reynolds, Navin Rao, Ph.D., Mark Selby, Jim Paulson, David Rothstein, Sheng Xiao to help bring more targeted tissue and antigen specific therapies to patients in need. This is your last chance to register and take advantage of our largest discounts which end this Friday, September 15. Click here to learn more information: https://ter.li/ot42ia #drugdevelopment #drugdiscovery #autoimmunity

Are you Interested in knowing more about / investing in early stage research related to longevity and healthspan? Check out VitaDAO if you said YES!

On May 15th we announced a partnership with Enable Injections to develop a combination product to treat advanced Parkinson's disease. Our chemistry team at Serina spent four years trying to solve the challenges of programming the release of apomorphine from our proprietary POZ polymer. We solved it. We are relentless. SER-252 is a potential breakthrough therapy for advanced disease. We anticipate entering clinical studies in 2025 with a twice per week subcutaneous injection of apomorphine that has the potential to reduce “OFF” time, with no adverse skin reactions and no need for a doctor or nurse to administer it. SER-252 is a preventive therapy (not a rescue therapy) with the potential to increase “ON” time, prevent dyskinesia, and may allow some patients to titrate off all L-DOPA. Leveraging our partnership with Enable Injections, SER-252 is being developed using enFuse®, the innovative wearable drug delivery platform from Enable that allows patient self-administration with rapid treatment time. Go to www.enableinjections.com and www.serinatherapeutics.com to learn more.

October 18 Breaking New Ground in Cancer, Immune Disorders and Infection Register here! https://lnkd.in/gCT3XnPg We'll highlight the state-of-the-art research taking place at Rosalind Franklin University of Medicine and Science & detail the novel approaches for diagnosing and treating disease. #ChicagoBiotech #Biotech #lifesciences